pediatrics-neonatal-healthcare-2017-posters-abstracts

Page 51

Pediatrics & Neonatal Healthcare 2017

http://pediatrics.cmesociety.com

September 11-12, 2017 Los Angeles, CA, USA

World Pediatrics &

Neonatal Healthcare Conference

Journal of Pediatric Health Care and Medicine Volume 1, Issue 1

Notes:

High incidence of cisplatin-induced ototoxicity in paediatrics in Johannesburg, South

Africa

Mukovhe Chad Phanguphangu

University of Cape Town, South Africa

isplatin, a highly effective chemotherapeutic is associated with high incidences of ototoxicity. This cross-

sectional retrospective study documents the incidence of cisplatin-induced ototoxicity in paediatrics

utilising data obtained during ototoxicity monitoring of a total of 196 paediatric patients who underwent cisplatin

chemotherapy in Johannesburg, South Africa, between January 2015 and December 2016, through conventional

audiometry, extended high frequency audiometry and distortion product otoacoustic emissions (DPOAEs).

Descriptive and inferential statistics were used for data analysis. Twelve percent of the participants did not develop

ototoxicity during treatment. 84% of the participants developed hearing loss of varying degrees during treatment.

Additionally, 4% presented with delayed onset of hearing loss detected at 6-weeks post-treatment. While 60% of

participants presented with profound SNHL, 12% had a moderate to severe high frequency sensorineural hearing

loss (SNHL) and 12% had a SIOP grade 4 ototoxic shift in the extended high frequency range. Diminished

DPOAEs were observed in 92% of the participants. Only 66% of the participants were diagnosed with ototoxicity

using conventional audiometry. Three percent of the participants presented with mixed hearing loss while 4%

had conductive hearing loss. In addition, 78% of the participants presented with chronic cerumen impaction

throughout the course of chemotherapy. High pitched tinnitus was reported in 56% of the participants. This study

highlights a high incidence of cisplatin-induced ototoxicity in paediatrics and thus recommends prospective

studies in oto-protection to prevent the negative impacts of cisplatin-induced hearing loss in paediatrics.